Palisade Bio Appoints Two IBD Experts to Advisory Board
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 12h ago
0mins
Palisade Bio announced the appointment of Laurent Peyrin-Biroulet, MD, PhD and David Rubin, MD, two internationally recognized leaders in inflammatory bowel disease, to its Clinical Advisory Board.
Get Free Real-Time Notifications for Any Stock
Monitor tickers like PALI with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
Analyst Views on PALI
Wall Street analysts forecast PALI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PALI is 13.00 USD with a low forecast of 7.00 USD and a high forecast of 25.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 1.670
Low
7.00
Averages
13.00
High
25.00
Current: 1.670
Low
7.00
Averages
13.00
High
25.00
About PALI
Palisade Bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and advancing therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. The Company’s lead product candidate, PALI-2108, is being developed as a treatment for patients living with inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Fibrostenotic Crohn’s disease (FSCD). The Company is conducting a Phase I human clinical trial of its lead product candidate, PALI-2108, for the treatment of UC. In UC mouse models, the Company has demonstrated the dose-dependent efficacy of PALI-2108. It utilizes dextran sodium sulfate (DSS)-induced UC mouse models and targets engagement in oxazolone-induced colitis. PALI-2108 targets the key phosphodiesterase-4 (PDE4) in colon tissues and prevents it from breaking down cyclic Adenosine Monophosphate (cAMP) molecules which regulate inflammation in the body.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Palisade Bio's PALI-2108 Clinical Data Selected for Two International IBD Meetings
- Clinical Data Presentation: Palisade Bio's PALI-2108 has been selected for poster presentations at two international inflammatory bowel disease meetings in January and February 2026, showcasing the drug's potential in ulcerative colitis treatment and enhancing the company's reputation in the biopharmaceutical sector.
- Immune Balance Restoration: PALI-2108 rapidly restores immune-epithelial balance in ulcerative colitis patients through gut-targeted PDE4B inhibition, indicating its clinical efficacy and potentially providing new treatment options for patients.
- Successful Clinical Trials: In a recent Phase 1b trial, PALI-2108 achieved a 100% clinical response in ulcerative colitis patients with no serious adverse events, demonstrating favorable tolerability and pharmacokinetics, which strengthens its market competitiveness.
- Future Research Plans: Palisade Bio plans to initiate a Phase 2 clinical study for PALI-2108 in 2026 to evaluate clinical remission and pharmacodynamic biomarkers in ulcerative colitis, further validating its therapeutic effects and expanding its indications.
Continue Reading
Palisade Bio Secures $500K Investment to Advance PALI-2108
- Strategic Investment: The Crohn’s & Colitis Foundation has approved a strategic equity investment of up to $500,000 in Palisade Bio through its IBD Ventures program, aimed at supporting the clinical and mechanistic development of PALI-2108, reflecting strong endorsement of the drug's potential.
- Clinical Progress: PALI-2108 achieved a 100% clinical response in the UC cohort with no serious adverse events, indicating favorable tolerability and pharmacokinetics in treating moderate to severe ulcerative colitis and fibrostenotic Crohn’s disease.
- R&D Plans: Palisade Bio is preparing to submit a Phase 2 Investigational New Drug application to the FDA in 2026 for PALI-2108, further advancing its clinical development to meet the urgent need for non-immunosuppressive therapies for patients.
- Market Potential: The targeted delivery design of PALI-2108 aims to minimize systemic side effects while maximizing anti-inflammatory and anti-fibrotic effects, which is expected to significantly enhance treatment options for IBD patients and strengthen the company's competitive position in the biopharmaceutical sector.
Continue Reading